Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 170Neoplasm Metastasis 13Prostatic Neoplasms, Castration-Resistant 11Metastatic Castration-resistant Prostate Cancer 7Neoplasms 6Metastatic Castration Resistant Prostate Cancer 6Breast Neoplasms 6Prostate Cancer Metastatic 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 3Genital Neoplasms, Male 3Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Diseases, Male 2Castration-resistant Prostate Cancer 2Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Sleep Initiation and Maintenance Disorders 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1

Interventions

zenocutuzumab 1enzalutamide 1Afatinib 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NSCLC Harboring NRG1 Fusion × Abiraterone Acetate × Clear all
NCT05588609 2026-04-27

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Partner Therapeutics, Inc.

Phase 2 Terminated
13 enrolled
GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡